Next Article in Journal
Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review
Next Article in Special Issue
Xanthine Oxidase/Dehydrogenase Activity as a Source of Oxidative Stress in Prostate Cancer Tissue
Previous Article in Journal
Impact of H19 Polymorphisms on Prostate Cancer Clinicopathologic Characteristics
Previous Article in Special Issue
Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation
Review

Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer

1
Mosaiques Diagnostics GmbH, 30659 Hannover, Germany
2
Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, 23538 Lübeck, Germany
3
Institut National de la Santé et de la Recherche Médicale (INSERM) U1048, Institute of Cardiovascular and Metabolic Diseases, 31432 Toulouse, France
4
Université Toulouse III Paul-Sabatier, 31400 Toulouse, France
5
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, UK
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(9), 658; https://doi.org/10.3390/diagnostics10090658
Received: 7 August 2020 / Revised: 24 August 2020 / Accepted: 28 August 2020 / Published: 31 August 2020
(This article belongs to the Special Issue Diagnostic Biomarkers in Prostate Cancer 2020)
Prostate cancer (PCa) is one of the most frequently diagnosed malignancies, and the fifth leading cause of cancer related mortality in men. For advanced PCa, radical prostatectomy, radiotherapy, and/or long-term androgen deprivation therapy are the recommended treatment options. However, subsequent progression to metastatic disease after initial therapy results in low 5-year survival rates (29%). Omics technologies enable the acquisition of high-resolution large datasets that can provide insights into molecular mechanisms underlying PCa pathology. For the purpose of this article, a systematic literature search was conducted through the Web of Science Database to critically evaluate recent omics-driven studies that were performed towards: (a) Biomarker development and (b) characterization of novel molecular-based therapeutic targets. The results indicate that multiple omics-based biomarkers with prognostic and predictive value have been validated in the context of PCa, with several of those being also available for commercial use. At the same time, omics-driven potential drug targets have been investigated in pre-clinical settings and even in clinical trials, holding the promise for improved clinical management of advanced PCa, as part of personalized medicine pipelines. View Full-Text
Keywords: biomarkers; drug targets; omics; prostate cancer biomarkers; drug targets; omics; prostate cancer
Show Figures

Figure 1

MDPI and ACS Style

Frantzi, M.; Hupe, M.C.; Merseburger, A.S.; Schanstra, J.P.; Mischak, H.; Latosinska, A. Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. Diagnostics 2020, 10, 658. https://doi.org/10.3390/diagnostics10090658

AMA Style

Frantzi M, Hupe MC, Merseburger AS, Schanstra JP, Mischak H, Latosinska A. Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. Diagnostics. 2020; 10(9):658. https://doi.org/10.3390/diagnostics10090658

Chicago/Turabian Style

Frantzi, Maria, Marie C. Hupe, Axel S. Merseburger, Joost P. Schanstra, Harald Mischak, and Agnieszka Latosinska. 2020. "Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer" Diagnostics 10, no. 9: 658. https://doi.org/10.3390/diagnostics10090658

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop